Top 5 Tepezza Manufacturers (2026 Audit Report)

H2 2026 Market Trends for Tepezza

As of the second half of 2026, the market landscape for Tepezza (teprotumumab-trbw), a monoclonal antibody developed by Horizon Therapeutics (now part of Amgen following the 2023 acquisition), reflects a dynamic shift driven by increased market penetration, evolving competition, expanded patient access, and ongoing clinical research in thyroid eye disease (TED).

1. Continued Market Dominance in Thyroid Eye Disease
   Tepezza remains the leading biologic therapy for moderate to severe TED, a rare autoimmune condition associated with Graves’ disease. By H2 2026, the drug has solidified its position as the standard of care due to its demonstrated efficacy in reducing proptosis (eye bulging), diplopia (double vision), and overall disease activity. Real-world evidence continues to support its superior outcomes compared to traditional treatments like corticosteroids or orbital surgery.

2. Increased Patient Access and Insurance Coverage
   Following advocacy efforts and improved payer negotiations, Tepezza has seen broader insurance coverage across commercial and Medicaid plans in the U.S. By H2 2026, prior authorization hurdles have decreased due to clearer clinical guidelines from endocrinology and ophthalmology associations, contributing to faster treatment initiation. Additionally, Amgen has expanded its patient support programs, including co-pay assistance and case management, further improving access.

3. Impact of Biosimilar and Pipeline Competition
   While no biosimilar to Tepezza has launched by H2 2026—due to complex manufacturing and regulatory challenges—several pipeline therapies are advancing. Companies are exploring alternative IGF-1R inhibitors and novel immunomodulators. However, Tepezza maintains a first-mover advantage, and its robust clinical data continue to support premium pricing and physician preference.

4. Expanding Global Footprint
   Outside the U.S., Tepezza is gaining traction in European and Asian markets. Regulatory approvals in several EU countries and Japan have been secured, with reimbursement discussions ongoing. Though adoption is slower internationally due to pricing constraints and healthcare system differences, H2 2026 marks the beginning of meaningful revenue diversification for Amgen.

5. Ongoing Clinical Research and Label Expansion
   Amgen is investing in post-marketing studies to explore lower dosing regimens, retreatment protocols, and long-term safety. Preliminary data from Phase 4 trials in H2 2026 suggest potential benefits for patients with recurrent TED, possibly leading to label expansion. Additionally, research into earlier intervention—before significant orbital tissue remodeling—could redefine treatment paradigms.

6. Financial Performance and Market Outlook
   Tepezza generated over $2 billion in annual revenue in 2025, and H2 2026 trends indicate sustained growth, driven by increased diagnosis rates, heightened awareness among endocrinologists and oculoplastic surgeons, and improved screening tools. Despite pricing pressures, Amgen is maintaining margins through operational efficiencies and lifecycle management strategies.

7. Challenges and Risks
   Key challenges include potential safety concerns related to hearing loss and hyperglycemia, which remain under FDA monitoring. Additionally, legal proceedings related to patent exclusivity—particularly around method-of-use patents set to expire in 2027—are closely watched, as they could influence market exclusivity and future competition.

Conclusion:
In H2 2026, Tepezza continues to lead the TED treatment market with strong clinical, commercial, and strategic momentum. Under Amgen’s commercial infrastructure, the drug is well-positioned to maintain dominance through 2027, though long-term success will depend on managing competition, expanding globally, and reinforcing its value proposition through real-world evidence and potential label expansions.

Common Pitfalls Sourcing Tepezza (Quality, IP)

Sourcing Tepezza (teprotumumab-trbw), a biologic medication used to treat Thyroid Eye Disease (TED), presents several challenges, particularly concerning product quality and intellectual property (IP) rights. Being aware of these pitfalls is crucial for patients, healthcare providers, and payers to ensure safe and legitimate access.

Quality-Related Pitfalls

1. Risk of Counterfeit or Substandard Products
Due to Tepezza’s high cost and demand, there is a growing risk of counterfeit or substandard versions entering unregulated supply chains. These may lack proper active ingredients, have incorrect dosages, or be stored improperly (e.g., not maintained under required cold-chain conditions), compromising efficacy and patient safety.

2. Improper Storage and Handling
Tepezza is a sensitive monoclonal antibody that requires strict temperature control (typically 2°C to 8°C). Sourcing through unauthorized distributors or gray-market channels increases the risk of temperature excursions during transport or storage, potentially degrading the drug and rendering it ineffective or harmful.

3. Lack of Regulatory Oversight in Alternative Supply Chains
Sourcing from non-FDA-regulated or international suppliers—especially through online pharmacies or third-party brokers—may bypass critical quality controls. Facilities may not adhere to Current Good Manufacturing Practices (cGMP), increasing the risk of contamination or inconsistent product quality.

Intellectual Property (IP)-Related Pitfalls

1. Patent Infringement and Legal Exposure
Tepezza is protected by multiple patents held by Horizon Therapeutics (now part of Amgen), including composition-of-matter, method-of-use, and formulation patents. Sourcing biosimilars or unauthorized versions before patent expiry may expose providers or distributors to legal liability for patent infringement.

2. Misrepresentation of Biosimilar Availability
As of now, there are no FDA-approved biosimilars for Tepezza. Some suppliers may falsely claim to offer equivalent or “generic” versions, misleading buyers. This not only violates IP laws but also poses serious health risks due to unverified product equivalence.

3. Gray Market Sourcing and IP Violations
Importing Tepezza from countries where it may be sold at lower prices—without authorization from the IP holder—can constitute parallel importing, which may infringe on exclusivity rights and distribution agreements. This undermines the manufacturer’s IP rights and may lead to supply chain disruptions or legal action.

4. Unauthorized Distribution Channels
Purchasing Tepezza through unauthorized distributors or intermediaries not affiliated with Horizon/Amgen or authorized wholesalers increases the risk of IP violations and may result in the distribution of diverted or illegitimate product.

Conclusion

Sourcing Tepezza requires diligence to avoid compromising patient safety and legal compliance. Stakeholders should procure the medication exclusively through FDA-authorized channels, verify distributor legitimacy, and remain cautious of offers that seem unusually low in price. Staying informed about patent status and regulatory approvals is essential to avoid IP-related risks and ensure access to safe, high-quality treatment.

Logistics & Compliance Guide for Tepezza (teprotumumab-trbw)

This guide outlines key logistics and compliance considerations for the handling, distribution, and administration of Tepezza (teprotumumab-trbw), a prescription biologic medication used for the treatment of Thyroid Eye Disease (TED). Adherence to these guidelines ensures patient safety, regulatory compliance, and product integrity.

Storage and Handling Requirements

Tepezza must be stored and handled under strict temperature-controlled conditions to maintain stability and efficacy. The product is supplied as a lyophilized powder in a single-dose vial.

• Storage Temperature: Store vials at 2°C to 8°C (36°F to 46°F) in the original carton to protect from light.
• Do Not Freeze: Freezing can damage the product. If frozen, do not use.
• Refrigeration During Transport: All shipments must use validated cold chain packaging with temperature monitoring (e.g., data loggers) to ensure continuous refrigeration.
• In-Transit Monitoring: Temperature excursions must be documented and assessed per risk management protocols. Any exposure outside the 2°C–8°C range may render the product unsuitable for use.
• Reconstituted Product: After reconstitution with sterile water for injection, the solution should be used immediately or stored under refrigeration (2°C–8°C) and used within 24 hours. Do not freeze.

Distribution and Chain of Custody

Tepezza is distributed through a restricted network due to its specialized handling and high-cost nature. Only authorized healthcare providers and facilities may order and receive the product.

• Authorized Distribution Channels: Tepezza is available through specialty pharmacies and distributors enrolled in the manufacturer’s (Horizon Therapeutics) distribution program.
• Chain of Custody Documentation: Maintain complete documentation at each stage of distribution (manufacturer → distributor → healthcare facility). This includes shipping records, temperature logs, and chain-of-custody forms.
• Direct-to-Patient (DTP) or Direct-to-Clinic (DTC): Most administrations occur in clinical settings. If DTP is used, ensure patient/caregiver training and validated cold chain delivery methods.

Prescribing and Patient Eligibility

Tepezza is indicated for adults with active Thyroid Eye Disease. Proper patient selection and documentation are critical for compliance.

• FDA-Approved Indication: Confirm diagnosis of active TED through clinical evaluation (e.g., clinical activity score, imaging, ophthalmologic assessment).
• Prior Authorization (PA): Most insurers require PA. Submit medical records, diagnosis codes (e.g., H06.21 for TED), and justification for therapy.
• Patient Registry Enrollment: Patients may be required to enroll in a safety registry (e.g., Horizon’s iNSTRuCT registry) to monitor long-term outcomes and adverse events.

Administration Protocols

Tepezza is administered intravenously by healthcare professionals in a certified infusion center or clinical setting.

• Dosing Schedule: 10 mg/kg IV infusion during Week 0, followed by 20 mg/kg IV every 3 weeks for a total of 7 additional infusions (8 infusions total).
• Infusion Duration: Each infusion lasts approximately 60 minutes. Premedication with antihistamines or corticosteroids may be considered to reduce infusion reactions.
• Observation Period: Monitor patients during and for at least 60 minutes post-infusion for hypersensitivity or infusion-related reactions.
• Documentation: Record infusion details (dose, time, lot number, adverse events) in the patient’s medical record and the manufacturer’s safety database as required.

Adverse Event Reporting and Safety Monitoring

Healthcare providers are responsible for monitoring and reporting adverse events (AEs) associated with Tepezza.

• Common Adverse Reactions: Include muscle spasm, nausea, alopecia, diarrhea, fatigue, hyperglycemia, and hearing impairment.
• Serious Risks: Potential for infusion reactions, hyperglycemia (especially in diabetics), and hearing disturbances.
• Mandatory Reporting: Report serious AEs to the manufacturer (Horizon Therapeutics) and FDA’s MedWatch program (Form FDA 3500B) within 15 calendar days.
• Pregnancy Exposure Registry: For patients who become pregnant during or after treatment, report to the Tepezza pregnancy registry immediately.

Regulatory and Billing Compliance

Ensure all aspects of prescribing, dispensing, and administration comply with federal, state, and payer regulations.

• HCPCS Code: J9305 – Injection, teprotumumab-trbw, 10 mg.
• Accurate Coding and Documentation: Use correct ICD-10 diagnosis codes (e.g., H06.21) and CPT codes for infusion services (e.g., 96365, 96366).
• Anti-Kickback Statute (AKS) and Stark Law: Avoid prohibited financial arrangements. Manufacturer co-pay assistance programs must be used in compliance with federal guidelines.
• 340B Program Compliance: Covered Entities participating in the 340B Drug Pricing Program must adhere to program requirements, including patient eligibility and audit readiness.

Product Accountability and Inventory Management

Maintain rigorous inventory control to prevent diversion, waste, or expiration.

• Lot Tracking: Track all vials by lot number from receipt through administration.
• Expiration Dating: Do not use vials past the expiration date printed on the label.
• Waste Disposal: Dispose of unused or expired product according to federal, state, and facility hazardous waste protocols.
• Security: Store Tepezza in a locked, access-controlled refrigerator with temperature monitoring.

Training and Staff Competency

Ensure all personnel involved in ordering, handling, or administering Tepezza are trained.

• Required Training: Staff should complete training on biologic handling, infusion protocols, AE recognition, and emergency response.
• Documentation of Training: Maintain training records for audits and accreditation purposes.
• Emergency Preparedness: Ensure availability of emergency medications (e.g., epinephrine, antihistamines) and equipment to manage anaphylaxis.

Audit and Documentation Retention

Maintain records to support compliance with regulatory and payer requirements.

• Retention Period: Keep records (prescriptions, infusion logs, temperature data, AE reports) for a minimum of 7 years, or as required by local law.
• Audit Readiness: Facilities should be prepared for inspections by payers, regulatory bodies, or the manufacturer.
• Electronic Health Record (EHR) Integration: Utilize EHR systems to ensure accurate, real-time documentation of administration and safety events.

Adherence to this Logistics & Compliance Guide ensures the safe and effective use of Tepezza while maintaining alignment with regulatory standards and manufacturer requirements. Always refer to the most current prescribing information and manufacturer communications for updates.

Declaration: Companies listed are verified based on web presence, factory images, and manufacturing DNA matching. Scores are algorithmically calculated.